Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

317
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
317
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

234
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
234
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

212
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
212
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

208
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
208
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

188
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
188
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nonlifestyle Treatment of Prediabetes.

Clinical diabetes : a publication of the American Diabetes Association·2025
Same author

Comment on Pasanisi et al. Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial. Diabetes Care 2025;48:265-272.

Diabetes care·2025
Same author

Definition of Overbasalization.

Clinical diabetes : a publication of the American Diabetes Association·2025
Same author

The Effective Use by Primary Care Clinicians of a Comprehensive Computerized Insulin Dose Adjustment Algorithm.

Journal of diabetes science and technology·2024
Same author

Comment on Mittendorfer et al. Insulin Hypersecretion as Promoter of Body Fat Gain and Hyperglycemia. Diabetes 2024;73:837-843.

Diabetes·2024
Same author

In adults with hypertension and high CV risk, intensive vs. standard BP-lowering therapy reduced major vascular events.

Annals of internal medicine·2024
Same journal

Real-World Performance of the MiniMed 780G Advanced Hybrid Closed Loop Automated Insulin Delivery System in Greece.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2026
Same journal

Real-World Glucometric Outcomes of the MiniMed 780G Advanced Hybrid Closed-Loop System in Users with Type 1 Diabetes in Spain.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2026
Same journal

Basal Insulin Adherence in Patients with Type 2 Diabetes Mellitus in Routine Clinical Practice in Spain: Clinical and Economic Impact.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2026
Same journal

Novel Clinical and Pre-clinical Obesity Estimates in Older Indian Adults: Insights from a Nationally Representative Dataset.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2026
Same journal

Treatment Options for Patients with Maturity-Onset Diabetes of the Young (MODY): A Systematic Review of Literature: 2026 Update.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2026
Same journal

Overlap of Gestational Diabetes Mellitus and Pre-eclampsia: A Scoping Review.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2026
See all related articles

Related Experiment Video

Updated: Jul 21, 2025

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.3K

Should Prediabetes be Treated Pharmacologically?

Mayer B Davidson1

  • 1Charles R. Drew University, 1731 East 120th Street, Los Angeles, CA, 90059, USA. mayerdavidson@cdrewu.edu.

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|July 25, 2023
PubMed
Summary
This summary is machine-generated.

Pharmacological treatment for prediabetes is not recommended. However, weight loss achieved with GLP-1 receptor agonists or dual agonists shows promise for improving insulin resistance and reducing diabetes risk.

Keywords:
Cardiovascular diseaseGIPGLP-1 AgonistsMetabolic syndromeObesityPrediabetes

More Related Videos

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.7K
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.9K

Related Experiment Videos

Last Updated: Jul 21, 2025

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.3K
An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.7K
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.9K

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Pharmacology

Background:

  • Prediabetes lacks independent cardiovascular risk; metabolic syndrome factors drive risk.
  • Diagnostic criteria vary, leading to prevalence estimates from 6% to 38%.
  • Many individuals with prediabetes spontaneously recover or do not progress to diabetes.

Purpose of the Study:

  • To evaluate the pharmacological treatment of prediabetes.
  • To assess the efficacy of current medications in addressing underlying pathophysiology.
  • To explore alternative therapeutic strategies for prediabetes management.

Main Methods:

  • Review of existing literature on prediabetes diagnosis and treatment.
  • Analysis of pharmacological interventions and their long-term effects.
  • Consideration of weight-loss interventions and their impact on insulin resistance.

Main Results:

  • Pharmacological treatment of dysglycemia in prediabetes is not supported by current evidence.
  • Discontinuation of glucose-lowering drugs does not alter insulin resistance or secretion.
  • Weight loss of 15-20% via GLP-1 receptor agonists or dual agonists shows potential.

Conclusions:

  • Pharmacological management of prediabetes dysglycemia is not warranted.
  • High-dose GLP-1 receptor agonists and dual GIP/GLP-1 agonists offer significant weight reduction, a promising therapeutic avenue.
  • Achieved weight loss can improve insulin resistance and endogenous insulin effectiveness, potentially lowering diabetes incidence.